Preventing blood clots in hypertrophic cardiomyopathy with rivaroxaban
Part of Heart & circulation clinical trials.
This trial tests if the blood thinner rivaroxaban can prevent strokes in people with hypertrophic cardiomyopathy who have early signs of damage in their left atrium (the heart's upper chamber). You may qualify if you have this condition, are in a normal heart rhythm, and are between 40 and 80 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You weigh between 110 and 265 pounds (50 to 120 kilograms).
- Your heart is in a normal rhythm (sinus rhythm).
- You have been diagnosed with primary hypertrophic cardiomyopathy (not caused by other conditions like high blood pressure or heart valve problems).
- Your left atrial strain (a measure of how well your heart's upper chamber functions) is 20% or less as confirmed by a central lab.
- If you could become pregnant, you must use highly effective birth control for at least 14 days before starting treatment, during the study, and for 4 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how the heart's electrical signals work in people with hypertrophic cardiomyopathy (a condition where the heart muscle becomes thickened) who also have atrial fibrillation (a type of irregular heartbeat). The goal is to understand these signals better during a planned ablation procedure, which is a treatment to fix the irregular rhythm.
This trial tests how to use a blood thinner in people after a recent heart attack who have a clot in the left heart chamber confirmed by heart MRI. It may help lower the risk of the clot causing serious complications, but it also requires careful bleeding-safety screening.
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
This study tests a blood thinner called rivaroxaban in children who have a blood clot inside the heart. The goal is to see if it safely and effectively dissolves the clot, potentially avoiding the need for stronger treatments.
This trial tests a blood thinner called rivaroxaban (Xarelto) given right after heart valve surgery with a tissue valve. It aims to see if it can prevent blood clots or strokes safely in the early recovery period.
This trial tests a blood thinner, rivaroxaban, to see if it can prevent blood clots from forming in the heart after a specific type of heart attack (STEMI) that affects the front part of the heart.
Hear when a new Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.